

01-27-2003

FORM PTO-1595
1-31-92



U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

102342907

.Y

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

MIRD 1-24-03

1. Name of conveying party(ies):
Otsuka Pharmaceutical Co., Ltd.

 _____ Individual(s) _____ Association
 _____ General Partnership _____ Limited Partnership
XXX Corporation - Japan
 _____ Other _____
 Additional name(s) of conveying party(ies) attached? ___ Yes **XXX** No

2. Name and address of receiving party(ies):
 Name: Japan Immunoresearch Laboratories, Co., Ltd.
 Internal Address: _____
 Street Address: 351-1 Nishiyokote-machi
 City/State: Takasaki, Gunma Country: JAPAN
 _____ Individual(s) citizenship _____
 _____ Association _____
 _____ Limited Partnership _____
XXX Corporation - State Japan
 _____ Other _____
 If assignee is not domiciled in the United States, a domestic representative designation is attached: **XXX** Yes _____ No
 (Designations must be a separate document from Assignment)
 Additional name(s) & address(es) attached? ___ Yes **XXX** No

3. Nature of conveyance:
XXX Assignment _____ Merger
 _____ Security Agreement _____ Change of Name
 _____ Other _____
 Execution Date: November 12, 2001

4. Application number(s) or registration number(s):
 A. Trademark Application No.(s)
75/390797
 Additional numbers attached? _____ Yes **XXX** No

B. Trademark Registration No.(s)

 Additional numbers attached? _____ Yes **XXX** No

5. Name and address of party to whom correspondence concerning document should be mailed:
 Name: Stanley W. Sokoloff
 Internal Address:
BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN
 Street Address: 12400 Wilshire Boulevard, 7th Floor
 City: Los Angeles State: CA ZIP: 90025

6. Total number of applications and registrations involved: 1
 7. Total fee (37 CFR 3.41).....\$ 40.00
XXX Enclosed
XXX Deficiency of fees authorized to be charged to deposit account
 8. Deposit account number:
02-2666
 (Attach duplicate copy of this page if paying by deposit account)

CHARGE FEE

DO NOT USE THIS SPACE

9. Statement and signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.
Stanley W. Sokoloff Stanley W. Sokoloff January 29, 2002
 Name of Person Signing Signature Date
 Total number of pages comprising cover sheet: 4

ASSIGNMENT

WHEREAS, OTSUKA PHARMACEUTICAL CO., LTD. a Japanese corporation, having a principal address at 2-9, Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as "Assignor"), has interested to use the following trademark and has filed the following application indicating such intention, but has not yet filed allegations of use under §§1(c) or 1(d) of the Trademark Act:

<u>Mark</u>	<u>Serial No.</u>	<u>Filing Date</u>
RLP	75/390737	November 17, 1997

WHEREAS, Assignor is assigning the mark in the above-identified application as part of the entire business to which the mark pertains as required by 15U.S.C. §1060;

WHEREAS, JAPAN IMMUNORESEARCH LABORATORIES, CO., LTD., a Japanese corporation, having a principal address at 351-1, Nishiyokote-machi, Takasaki, Gunma, Japan (hereinafter referred to as "Assignee"), is desirous of acquiring said service mark and the pending intent-to-use application.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby assigns to Assignee all right, title and interest in and to said trademark and said intent-to-use application therefor, together with the goodwill of the business symbolized by said trademark and application to register same.

OTSUKA PHARMACEUTICAL CO., LTD.
(Assignor)

Date: November 12, 2001

By: 

Name: Kazuhiro Tomita

Title: Executive Director on Board

CONFIRMATION of BUSINESS ASSIGNMENT for RLP


This is to confirm the Business assignment relating to the diagnostics for determination of the level of remnant like particular in serum in human body (hereinafter referred to as "RLP business") from Otsuka Pharmaceutical Co., Ltd., having a principal office at 2-9, Kanda Tsukasa-cho, Chiyoda-ku, Tokyo, Japan (hereinafter referred to as "Otsuka") to Japan Immunoresearch Laboratories Co., Ltd., having a principal office at 351-1, Nishiyokote-machi, Takasaki, Gunma, Japan (hereinafter referred to as "Jimro").

Since RLP business in Japan was assigned from Otsuka to Jimro on March 15, 1993 and Jimro has been engaging in the research and development works for getting marketing approval from US FDA and consequently Jimro got such marketing approval for RLP diagnostic kit for the diagnosis of familial hyperlipoproteinemia and hepatic hyperlipidemia in August 2000.


Considering these circumstances in the USA Otsuka and Jimro hereby agree that RLP business in USA shall be handled by Jimro and also agree to assign the US trademark application Serial No. 75/390737 RLP under name of Otsuka shall be assigned to Jimro.

November 12, 2001

November 14, 2001



Kazuhiro Tomita
Executive Director on Board
Otsuka Pharmaceutical Co., Ltd.



Masakazu Adachi
President
Japan Immunoresearch
Laboratories Co., Ltd.

DESIGNATION OF DOMESTIC REPRESENTATIVE

Stanley W. Sokoloff of BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN, whose postal address is 12400 Wilshire Boulevard, Seventh Floor, Los Angeles, California 90025 is hereby designated Applicant's representative upon whom notices or process in proceedings affecting the mark may be served.

JAPAN IMMUNORESEARCH LABORATORIES,
CO., LTD.

Date: 11/14/01

BY: 

Name: Masakazu Adachi

Title: President